IM

TRANS	SMITTA	L OF INFORMA (Under 37 CFF	11	cket No. 6096							
In Re App	lication Of	: Richard James I	Lewis et al. JUL 0.3 2006								
Applicat	ion No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.					
10/53	7,088	June 2, 2005	Unassigned	23389	Unassigned	9222					
Title: NOVEL X-CONOTOXIN PEPTIDES (-II)											
į	Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450										
			37 CFR 1.97(b)								
t t	of a natior hree mon application	nal application other ths of the date of en it before the mailing	atement submitted herewith is I than a continued prosecution atry of the national stage as se of a first Office Action on the mest for continued examination u	application und t forth in 37 CF nerits, or before	der 37 CFR 1.5 R 1.491 in an ir the mailing of a	3(d); within nternational					
			37 CFR 1.97(c)								
(2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:										
	☐ the statement specified in 37 CFR 1.97(e);										
			OR								
	☐ the	fee set forth in 37 Cl	FR 1.17(p).								

ŤRÁNSMITTA		TION DISCLOSU		TEMENT	8 1	eket No. 6096
In Re Application of	: Richard James	Lewis et al.	106 L			
Application No.	Filing Date	Examiner	GE CO	Customer No.	Group Art Unit	Confirmation No.
10/537,088	June 2, 2005	Unassigned		23389	Unassigned	9222
Title: NOVEL X-0	CONOTOXIN PEPT	IDES (-II)				
	(Only on	Paymen	t of Fee	fee set forth in 37	CFR 1.17(p))	•
The Director as described as described as described as described as described as characteristics. Payment by WARNING included concluded concluded account is being account is being account and Transperse (Date)	ed below. large the amount of edit any overpayment arge any additional for credit card. Form Fig.: Information on the cate of Transmission is a document and authorizing facsimile transmitted demark Office (Fa Printed Name of Person Signature	ee required. PTO-2038 is attached. is form may become e credit card information by Facsimile* ation to charge deposit to the United States	public. (ation and Color as first "Commis 22313-14 J	Credit card info l authorization ertificate of Mai certify that this co United States Pos class mail in signer for Patents 150" [37 CFR 1.8(a une 28, 2006 (Date)	ormation should on PTO-2038. Illing by First Claterrespondence is better that Service with sufficient an envelope at P.O. Box 1450, All on	eing deposited ricient postage addressed to lexandria, VA
Registration No. 56 Scully, Scott, Murj 400 Garden City P Garden City, New (516) 742-4343	phy & Presser, P.C. Plaza-STE 300					

cc: XZ:ab



Richard James Lewis et al. Applicants:

Examiner:

Unassigned

Serial No:

10/537,088

Art Unit:

Unassigned

Filed:

June 2, 2005

Docket:

16096

For:

NOVEL χ -CONOTOXIN PEPTIDES (-II) **Dated:**

June 28, 2006

Confirmation No: 9222

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. International Publication No. WO 98/22126, published May 28, 1998;

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 28, 2006.

Dated: June 28, 2006

- 2. International Publication No. WO 91/07980, published June 13, 1991;
- 3. International Publication No. WO 96/14079, published May 17, 1996;
- 4. International Publication No. WO 96/40064, published December 19, 1996;
- 5. International Publication No. WO 98/05309, published February 12, 1998;
- 6. International Publication No. WO 98/02148, published January 22, 1998;
- 7. International Publication No. WO 98/51668, published November 19, 1998;
- 8. International Publication No. WO 97/30997, published August 28, 1997;
- 9. International Publication No. WO 97/01351, published January 16, 1997;
- 10. United States Patent No. 6,767,896 B1, dated July 27, 2004, issued to McIntosh et al.;
- 11. United States Patent No. 6,794,361 B1, dated September 21, 2004, issued to Lewis et al.;
- 12. United States Patent No. 5,587,454, dated December 24, 1996, issued to Justice et al.;
- 13. United States Patent Application Publication No. 2005/0054827 A1, dated March 10, 2005 to Lewis et al.;
- 14. Bowersox, S.S. et al., "Selective N-Type Neuronal Voltage-Sensitive Calcium Channel Blocker, SNX-111, Produces Spinal Antinociception in rat Models of Acute, Persistent and Neuropathic Pain", *J. Pharmacol Exp. Ther.*, 279 (3): 1243-1249 (1996);
- 15. Krames, Elliot S. et al., "Intrathecal D-Ala²⁻D-Leu⁵-enkephalin (DADL) Restores Analgesia in a Patient Analgetically Tolerant to Intrathecal Morphine Sulfate", *Pain*, *24*: 205-209 (1986);
- Takagi, H. et al., "Analgesic Effect of L-threo-3-4-dihydroxyphenylserine (L-DOPS) in Patients with Chronic Pain", European Neuropsychopharmacology, 6: 43-47 (1996);
- 17. Eisenach, C. et al., "Cerebrospinal Fluid Norepinephrine and Acetylcholine Concentrations During Acute Pain", *Anesth Analg*, 82: 621-626 (1996);
- 18. Dubner, R. et al., "The Neurobiology of Pain and Its Modulation", *The Clinical Journal of Pain, 5(Suppl 2)*: S1-S6 (1989);

19. Dyck, P.J et al., "New Understanding and Treatment of Diabetic Neuropathy", The New England Journal of Medicine, 326(19):1287-1288 (1992);

. 4

- 20. Atkinson, J. H. et al., "A Placebo-controlled Randomized Clinical Trial of Nortriptyline for Chronic Low Back Pain", *Pain*, 76: 287-296 (1998);
- 21. Mico, J. A., et al., "Analgesic, Sedative and Antidepressent Effects of Noradrenergic Antidepressants Related to Beta-Adrenoceptors", *European Neuropsychopharmacology, S162*, P.1.086, Abstract (1997);
- 22. Springer, J. P. et al., "Facilitatory and Inhibitory Effects of Selective Norephinephrine Reuptake Inhibitors on Hypogastric Nerve-Evoked Urethral Contractions in the Cat: A Prominent Role of Urethral β-Adrenergic Receptors", The Journal of Urology, 152: 515-519 (1984);
- 23. Dinan, T. G. et al., "Assessment of Central Noradrenergic Functioning in Irritable Bowel Syndrome Using a Neuroendocrine Challenge Test", *Journal of Psychosomatic Research*, 34(5): 575-580 (1990);
- 24. Leung, D. et al., "Protease Inhibitors: Current Status and Future Prospects", J. Med Chem, 43(3): 305-341 (2000);
- 25. O'Neill, M. J. et al., "Effects of Ca²⁺ and Na⁺ channel inhibitors in vitro and in global cerebal ischaemia in vivo", *European Journal of Pharmacology*, 332: 121-131 (1997);
- 26. Eisenach, J. C. et al., "Intrathecal, but Not Intravenous, Clonidine Reduces Experimental Thermal or Capsaicin-Induced Pain and Hyperalgesia in Normal Volunteers", *Anesth Analg*, 87: 591-596 (1998);
- 27. Marban, E. et al., "Structure and Function of Voltage-Gated Sodium Channels", *Journal of Physiology*, 508.3: 647-657 (1998);
- 28. Yanagawa, Y. et al., "A Novel Sodium Channel Inhibitor from *Conus geographus*: Purification, Structure, and Pharmacological Properties", *Biochemistry*, 27: 6256-6262 (1988);
- 29. Ryan, R., et al., "Evaluation of an Enkephalin Analog in Men with Castor Oil-Induced Diarrhea", *Clinical Pharmacol Ther*, 39(1): 40-42 (1986);
- 30. Penttila, O, et al., "Studies of Rectal Mucosal Catecholamines in Ulcerative Colitis", *Annals of Clinical Research*, 7: 32-36 (1975).

Applicants are submitting copies of Reference Numbers 1-9 and 14-30. In accordance with the waiver of 37 C.F.R. § 1.98 (a)(2)(i) in effect as of June 30, 2003, Applicants are not required to submit copies of the above-cited U.S. Patent Reference Numbers 10-13.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(b), no statement or fee is required.

Respectfully submitted,

Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C. 400 Garden City Plaza – Suite 300 Garden City, New York 11530 (516) 742-4343

XZ:ahs/ab

					ATTY DOCKET NO.	·	APPLICATION N	10.	
	,		_		16096		10/5	537,088	
• • •	INFO	RMATIONOISCLOSURE	CITATION		APPLICANT(S)				
		(Use/several sheets if necess	ary)		Richard James Lewis e	t al.			
		الله موم الله			FILING DATE		GROUP ART UN	IJТ	
		2006			June 2, 2005		Una	ssigned	
		THE STATE OF THE S	U.S	. PATENT	DOCUMENTS				
*EXAMINER		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DAT	
		6,767,896 B1	7/27/2004	McIntosh	et al.				
		6,794,361 B1	9/21/2004	Lewis et a	ıl.				
-		5,587,454	12/24/1996	Justice et	al.			-	
								-	
					-				
•			U.S. PATEN	IT APPLICA	ATION PUBLICATIONS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DAT IF APPROF	
		2005/0054827 A1	3/10/2005	Lewis et a	ıl.				
									-
	•		FORE	IGN PATE	NT DOCUMENTS				
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANS	LATION
	 							YES	NO
		WO 98/22126	5/28/1998	PCT					
		WO 91/07980	6/13/1991	РСТ					
		WO 96/14079	5/17/1996	PCT					
		OTHER DOCUME	•	_	, Title, Date, Pertinent P	•	•		
		(1996)			Voltage-Sensitive Calcium C and Neuropathic Pain", J. I		•		
		Krames, Elliot S. et al., 'Tolerant to Intrathecal N	'Intrathecal D-A Morphine Sulfate	la2-D-Leu e'', Pain, 2	5-enkephalin (DADL) Rest 4: 205-209 (1986)	ores Analg	esia in a Patient	Analgetica	illy
EXAMINE	R				DATE CONSIDERED				
		l if reference considered, whether			nance with MPEP 609; Draw I	ine through	citation if not in c	onformance	and not

Form PTO-A820 (also form PTO-1449)

				AP	APPLICATION NO. 10/537,088			
'INFO	RMATION DISCLOSURE C	<i>yy</i> 301	16096 Richard James Lewis et	al.	ROUP ART			
	JUL 0	3 2006	June 2, 2005		Unas	ssigned		
	A A A A A A A A A A A A A A A A A A A	U.S. P	ATENT DOCUMENTS			FILING DATE		
MINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPROPRIATE		
AL								
				1	<u> </u>			
							_	
					1			
				<u> </u>		<u> </u>		
		U.S. PATENT	APPLICATION PUBLICATIONS		GUDOLASS	FILING DATE		
KAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPROPRIA	ATE	
ITIAL								
	 							
		<u> </u>		 	1			
		FORE	GIGN PATENT DOCUMENTS		SUBCLAS	TRANSL		
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS		YES	NO	
	WO 96/40064	12/19/1996	PCT		_			
	WO 98/05309	2/12/1998	PCT		_			
	WO 98/02148	1/22/1998	PCT					
	WO 98/51668	11/19/1998	PCT					
	WO 97/30997	8/28/1997	PCT				1	
		MENTS (Includ	ling Author, Title, Date, Pertine	ent Pages, E	Etc.)	Chronic Pain	"	
ļ	Takagi, H. et al., "A	nalgesic Effect of	L-threo-3-4-dihydroxyphenylserine	(L-DOPS) II	I Patients with	Chronic I am	,	
	1 1	a	id Noreninebili ille alla Accidioni					
	Analg, 82: 021-020		The (Clinical Journ	iai oi raili, ə(-	uppi 2). 02 0		
	Dyck, P.J et al., "Ne 326(19):1287-1288 (w Understanding	of Pain and Its Modulation , The Canal and Treatment of Diabetic Neurop	oathy", The N	ew England J	OUTHAL OF MICO		
EXAMINE			DATE CONSIDERED					
EXAMINE	1		on is in conformance with MPEP 609; to applicant.	Draw line thro	ough citation if	not in conforma	nce and	
			on in in conformance with MPEP 003.	Diaw into and	-3			

Form PTO-A820 (also form PTO-1449)

	-		OIP	<u> </u>	ATTY DOCKET NO. 16096		APPLICATION N 10/5	io. 3 7,088	
•	INFO	PRMATION DISCLOSURE (Use several sheets if necess.	CITATION	N E	Richard James Lewis e	t al.			
		,	JUL 0.3 21	AP61	FILING June 2, 2005		GROUP ART Una	ssigned	
			U.S.	PATENT	DOCUMENTS				
*EXAMINER		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATI	
				:-				:	
•			U.S. PATENT	APPLICA	ATION PUBLICATIONS				
*EXAMINER		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATI	
				-				-	
_				· · · ·					
						······································			
			FOREI	GN PATE	NT DOCUMENTS				
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSI YES	LATION NO
		WO 97/01351	1/16/1997	PCT					
				-					
:				-					
		OTHER DOCUME			, Title, Date, Pertinent F				·
		76: 287-296 (1998)			mized Clinical Trial of Nor				", Pain,
		1			pressent Effects of Noradre macology, S162, P.1.086, A				
		Springer, J. P. et al., "Fa Nerve-Evoked Urethral Urology, 152: 515-519 (1	acilitatory and Inl Contractions in th 1984)	hibitory F ne Cat: A	Effects of Selective Norephi Prominent Role of Urethr	nephrine Ro al \$-Adrene	euptake Inhibito ergic Receptors''	rs on Hypo , The Jour	gastric nal of
EXAMINE	R				DATE CONSIDERED	· · · · · · · · · · · · · · · · · · ·			
		al if reference considered, whethe			nance with MPEP 609; Draw	ine through	citation if not in c	onformance	and not

Form PTO-A820 (also form PTO-1449)

		OIPE	16096			
· INFOF	RMATION DISCLOSURE (Use several sheets if necess	CITATION Ary)	Richard James Lewis	et al.	OUP ART	
1111 01	i	ARE NO VIIII	FILING June 2, 2005		Unas	signed
		U.S.P	TENT DOCUMENTS			FILING DATE
		T COLUMN	NAME	CLASS	SUBCLASS	IF APPROPRIATE
MINER	DOCUMENT NUMBER	DATE				
AL.						
					 	
		-			<u> </u>	
					\	
			TON BURLICATIONS			
		U.S. PATENT	APPLICATION PUBLICATIONS	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
XAMINER	DOCUMENT NUMBER	DATE	NAME			IF AFFIIOT III
NITIAL						
		FOR	EIGN PATENT DOCUMENTS		aunoi Ai	TRANSLATION
	DOCUMENT NUMBER	DATE	COUNTRY	CLAS	S SUBCLA	YES NO
	DOCUMENT NOMBER					
 						
		- Uncli	uding Author, Title, Date, Pe	ertinent Pages	, Etc.)	o Using a Neuroendo
	OTHER D	5.6	entral Noradrenergic Function	IIA III III III	•	te Coming a xxx
	Challenge Test"	, Journal of Psychoso	omatic Research, 34(5): 575-580 S: Current Status and Future P	rospects", J. Me	ed Chem, 43(3)	: 305-341 (2000)
	1 1		i monthines in	Altio mm 0		
-	O'Neill, M. J. et Journal of Phar	t al., "Effects of Ca2- macology, 332: 121	s: Current Status and Future P + and Na+ channel inhibitors in -131 (1997) out Not Intravenous, Clonidine	Reduces Experi	mental Therm	al or Capsaicin-Induc
	Eisenach, J. C.	et al., "Intrathecal, t	+ and Na+ channel inflores and 131 (1997) out Not Intravenous, Clonidine olunteers", Anesth Analg, 87: 5	91-596 (1998)		
1			DATE CONSID ation is in conformance with MPEI n to applicant.			
EXAMIN						

Form PTO-A820 (also form PTO-1449)

Copyright 1994 LegalStar

P09C/REV04

			ATTY DOCKET NO. 16096	AF	PPLICATION NO 10/5	O. 3 7,088
` INFOR	MATION DISCLOSURE C	ITATION 48	Richard James Lewis et	al.	DOUB ADT	
	(Use several sheets if necessar	JUL 0 3 2006	FILING June 2, 2005		ROUP ART Una	ssigned
		U.S. PATE	NT DOCUMENTS		SUBCLASS	FILING DATE
MINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SOBCLASS	IF APPROPRIATE
IAL					-	
					 	
					 	
					 	
		U.C. DATENT APP	PLICATION PUBLICATIONS		<u> </u>	
			NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
(AMINER I	DOCUMENT NUMBER	DATE			+	1 74 1 100 1111
				1		
		 				
		FOREIGN	PATENT DOCUMENTS			
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES NO
				_		
	OTHER DOCUM	MENTS (Including /	Author, Title, Date, Pertine of Voltage-Gated Sodium Cha	nt Pages, E	nal of Physiolo	gy, 508.3: 647-657
	(1998)	A Novel Sodium Char	nnel Inhibitor from Conus geo	graphus: Pu	rification, Stru	cture, and
	Ryan, R., et al., "Eva	luation of an Enkepna	, 27: 6256-6262 (1988) lin Analog in Men with Casto sal Catecholamines in Ulcerati			
EVASSINED	(1975)	tudios of Attraction	DATE CONSIDERED			
EXAMINER	Initial if reference considered, w	nether or not citation is in	n conformance with MPEP 609;	Draw line thro	ugh citation if no	ot in conformance and
*EXAMINER: considered.	Initial if reference considered, with new Include copy of this form with new	t communication to app	licant.			J.S. DEPARTMENT OF COM

Form PTO-A820 (also form PTO-1449)